UCB to Acquire Zymvol Biomarker Research, Expanding Autoimmune Disease Portfolio
UCB announces plans to acquire Zymvol Biomarker Research, a leader in antibody treatments for autoimmune diseases. The deal strengthens UCB's pipeline...
UCB announces plans to acquire Zymvol Biomarker Research, a leader in antibody treatments for autoimmune diseases. The deal strengthens UCB's pipeline...
The U.S. Supreme Court faces a request to restore mail-order access to mifepristone amid legal challenges. UCB acquires Candid Therapeutics for $2.2 b...